Medical specialty – Rhinoplasty Digest http://rhinoplastydigest.com/ Wed, 23 Nov 2022 19:18:31 +0000 en-US hourly 1 https://wordpress.org/?v=5.9.3 https://rhinoplastydigest.com/wp-content/uploads/2021/07/icon-2021-07-08T154233.528.png Medical specialty – Rhinoplasty Digest http://rhinoplastydigest.com/ 32 32 OPD For Children Healthcare in Srinagar on Saturday – Kashmir Reader https://rhinoplastydigest.com/opd-for-children-healthcare-in-srinagar-on-saturday-kashmir-reader/ Wed, 23 Nov 2022 18:47:00 +0000 https://rhinoplastydigest.com/opd-for-children-healthcare-in-srinagar-on-saturday-kashmir-reader/ Srinagar: One of the best children’s hospitals in Delhi, Madhukar Rainbow Children’s Hospital is opening its OPD in Chanpora, Srinagar. Madhukar Rainbow Children’s Hospital and Birth Right have established a 150-bed super specialty tertiary care hospital, the first of its kind, with the most advanced perinatal center in Delhi. The hospital has well-planned and perfectly […]]]>

Srinagar: One of the best children’s hospitals in Delhi, Madhukar Rainbow Children’s Hospital is opening its OPD in Chanpora, Srinagar. Madhukar Rainbow Children’s Hospital and Birth Right have established a 150-bed super specialty tertiary care hospital, the first of its kind, with the most advanced perinatal center in Delhi. The hospital has well-planned and perfectly designed separate wings for children, women and pregnant women. The conceptually designed infrastructure has imaginatively designed interiors filled with rich colors, which facilitate the healing process. A dedicated and well-trained medical team also offers 24-hour intensive care and tertiary services in its neonatal, pediatric and perinatal wings.
Rainbow Children’s Hospital in conjunction with Florence Hospital, Chanpora, Srinagar, has taken this initiative to provide medical assistance to children. As part of this, specialist doctors from Madhukar Rainbow Children’s Hospital will be available at Florence, Chanpora, Srinagar, Jammu and Kashmir Hospital 190015 on 26 November 2022 (10:00 am – 3:00 pm)
This OPD will include Dr. Roshal Lal Kaul – Pediatric Neurologist, Dr. Harmanjeet Shah Singh – Pediatric Orthopaedist, Dr. Shandip Kumar Sinha – Pediatric Surgeon and Pediatric Urologist with special interest in Pediatric Minimally Invasive Surgery, Pediatric Endourology and Pediatric Reconstructive Urology, and Practices at Madhukar Rainbow Children’s Hospital, Malviya Nagar, Delhi
Where Children will be examined by these specialists from Madhukar Rainbow Children’s Hospital and they will be briefed accordingly. For more information, you can contact us at 8076250358.
Anuj Gupta, Regional Director of Madhukar Rainbow Children’s Hospital, said, “We are a leading chain of multi-specialty advanced pediatric, obstetrics and gynecology hospitals in India, operating 15 hospitals and three clinics in six cities, with a total bed capacity of 1,500 beds. . Our pediatric services include neonatal and pediatric intensive care, pediatric multispecialty services, pediatric quaternary care (including multiple organ transplants); while obstetrics and gynecology services include normal and complex obstetric care, multidisciplinary fetal care, perinatal genetic care, and fertility care.





]]>
Impending Change in Cardiac Care Delivery Creates Opportunities for Physicians and Hospitals https://rhinoplastydigest.com/impending-change-in-cardiac-care-delivery-creates-opportunities-for-physicians-and-hospitals/ Fri, 18 Nov 2022 22:34:41 +0000 https://rhinoplastydigest.com/impending-change-in-cardiac-care-delivery-creates-opportunities-for-physicians-and-hospitals/ Large, single-specialty cardiology practices were not uncommon in the 1990s and early 2000s, but that has changed over the past decade as hospitals and health systems have purchased cardiology practices, employed cardiologists directly and entered into professional services agreements (commonly referred to as “PSAs”) with cardiologists. The migration of private practicing cardiologists to hospitals has […]]]>

Large, single-specialty cardiology practices were not uncommon in the 1990s and early 2000s, but that has changed over the past decade as hospitals and health systems have purchased cardiology practices, employed cardiologists directly and entered into professional services agreements (commonly referred to as “PSAs”) with cardiologists. The migration of private practicing cardiologists to hospitals has been caused in large part by the large gap in service site charges between reimbursements to hospital outpatient departments (HOPD) and reimbursements for identical services provided in a physician’s office. independent or an outpatient surgery center (ASC).

Over the past 10 years, the main vehicles for the alignment of physicians with hospitals have been employment contracts, under which physicians are employees of the “captive” or “friendly” medical practice; or PSA, where hospitals provide administrative services to medical practices, and the practices remain independent. In this model, practices can access some of the benefits of salaried physicians, including advantageous hospital payment contracts.

According to a recent opinion piece in the Wall Street Journal “Medicare paid for hospital outpatient services almost twice as much since it remunerates independent physicians or CHWs for the same services. Even off-campus facilities, which are hospital-owned but otherwise identical to independent physicians, have until recently enjoyed higher rates.

There has been a major push for site-independent cardiac testing payments to migrate more services to outpatient settings. This gap could reduce Medicare spending by more than $150 billion over the next decade and reduce beneficiary spending on premiums and cost-sharing by more than $90 billion during that time. It is remarkable that such dramatic savings can be achieved without reducing the scope of services or otherwise compromising the quality of care. As increasing numbers of baby boomers retire and enroll in Medicare, the corresponding economic burden on Medicare trust funds necessitates these kinds of value-based cost-cutting measures.

This shift of services to outpatient settings will likely cause hospitals to break their contractual relationships with cardiologists, sending physicians back to private practice. Indeed, we have already observed this process with some of our clients. The outcomes present several challenges, including, but not limited to, the fact that cardiologists returning to private practice no longer have their own tax identification numbers (TINs) and payer contracts. In light of these logistical challenges and as a longer-term survival strategy, we will likely see a re-establishment of large cardiology practices, this time with the potential for private equity participation.

Until recently, there were few venture capital opportunities for cardiology practices, but that could change quite quickly. In the Wall Street Journal opinion piece, authors Neil M. Gheewala and Bobby Jindal noted, “Cardiac care is on the verge of a major transformation, but hospitals must not be left behind. Astute hospital administrators will already have anticipated the migration of cardiologists away from hospital care and begun to prepare for another kind of alignment with cardiologists. We foresee significant opportunities for single-specialty and/or multi-specialty roll-ups in which an investor, such as a private equity firm, purchases multiple medical practices and combines them into a larger practice. We also expect that Management Service Organizations (commonly referred to as “MSOs”) will continue to be used to achieve economies of scale in the provision of administrative services to firms.

Experienced healthcare lawyers who have represented both private practitioners and institutional providers throughout the dynamic changes in the healthcare landscape can lead this transformation, working with diverse stakeholders to develop and implement mutually beneficial alignment models, while ensuring compliance with applicable laws and regulations.

Photo: eakrin rasadonyindee, Getty Images

]]>
‘Fleishman Is In Trouble’ Review: The New Hulu Series Is Delicious (And Sexy) https://rhinoplastydigest.com/fleishman-is-in-trouble-review-the-new-hulu-series-is-delicious-and-sexy/ Tue, 15 Nov 2022 23:16:00 +0000 https://rhinoplastydigest.com/fleishman-is-in-trouble-review-the-new-hulu-series-is-delicious-and-sexy/ If Gone Girl received the recut trailer processing in the style of a Woody Allen movie, it would probably look like a lot Fleishman is in trouble. The new smart Hulu limited series, based on the novel of the same name by Taffy Brodesser-Akner, premieres November 17. There’s the failed marriage, the sad white man […]]]>

If Gone Girl received the recut trailer processing in the style of a Woody Allen movie, it would probably look like a lot Fleishman is in trouble. The new smart Hulu limited series, based on the novel of the same name by Taffy Brodesser-Akner, premieres November 17. There’s the failed marriage, the sad white man in his forties, and most importantly, the missing woman. But it’s also filled with anxious, neurotic New York Jews, philosophical back and forths, money and sex. Lots of sex.

Toby Fleishman (Jesse Eisenberg) is a recently divorced liver doctor with two kids who kinda hate him and a pretty down-to-earth bachelor pad in his dirt (complete with a set of broken vertical blinds). Despite his sad dismissal, Toby’s status is on the rise. On “apps” at least.

Read more: 8 Useful Hulu Tips You’re Probably Not Using and Netflix vs Hulu: Who has the best price, original shows and movies?

Once unlucky in love, with an undiagnosed eating disorder and a chip on his shoulder that both predate his marriage, Toby can’t believe his newfound social capital as a middle-aged divorcee in the within Tinder, a universe that did not exist. the last time it was on the market. Suddenly, he’s drowning in sexts from available single women who send pictures of “their side boobs, or their underbusts, or just their normal boobs,” says the show’s very opinionated narrator.

The identity of the narrator, at least for those who haven’t read the book, is a bit of a spoiler. But the TV adaptation reveals it halfway through Episode 1, and even earlier if you recognize Lizzy Caplan’s sardonic pace. Caplan plays Libby, Toby’s college friend, prematurely retired journalist, reluctant stay-at-home mom from Jersey, and a bit sad herself. Libby has her own issues, the show suggests.

Lizzy Caplan as Libby sits in a cafe across from Toby.

Lizzy Caplan as Toby’s friend Libby, also the show’s sardonic narrator.

Linda Kallerus/FX

Toby Reconnects With His College Friends – The Threesome Completed With Adam Brody Playing another lovely Seth – whom he hasn’t seen much since his marriage. At first glance, Toby’s ex-wife, Rachel Fleishman (played by Claire Danes in a power suit), is clearly the villain. She has the blunt bob of a careerist virago and a not-so-bubbling resentment, stoked by the anxieties typical of the Upper East Side upstart, as well as too many emails to respond to. But the show’s interest in first looks is only insofar as they can be reversed. Things are not what they seem.

When we meet Toby, Rachel has just left town unexpectedly for a yoga retreat, leaving Toby to take care of the two children. (“I have to secure my oxygen mask, you know? Before theirs,” she says.) The little inconvenience slowly turns daunting as Rachel misses phone calls, texts, and childcare, and Toby gets realizes that she may be missing. “Yeah, he was a terrible person,” Libby recounts as Toby begins to panic, “but bad things happen to terrible people too.”

Claire Danes as Rachel Fleishman stands in front of a contemplative-looking window.

Claire Danes’ Rachel has the right haircut for a villain, but things aren’t quite that simple.

Matthias Clamer/FX

At times, Libby’s stream-of-consciousness voiceover is distracting, making the scenes feel like documentary re-enactments. But Libby’s perspective is also a welcome antidote to Toby’s general “my ex is crazy” vibe, which will likely dampen sympathy from most viewers. The first two episodes may test the limits of your patience with the rich, white masculinity of it all. But you will be rewarded if you make it to Episode 3.

Like Gone Girl and other Rashomon-style marriage stories that thrill and accuse audiences by cutting the rug (Lauren Groff’s Fates and FuriesHBO Scenes from a wedding), Fleishman’s swinging pivot, a single line spoken by the always excellent J. Smith Cameron as Toby’s divorce attorney, will have you sitting in your chair and saying “Oh fuck…” The show’s title, superimposed on an upside-down New York skyline, does not specify who Fleishman is in trouble, after all.

The mystery of Rachel’s whereabouts is less a driving plot and more an excuse to examine how two people looking in the same direction can see such different viewpoints. If you’re hoping for a plot, stick with Gone Girl. But the Hulu adaptation is thrilling in other, more literary ways, thanks to executive director Brodesser-Akner who produced and wrote all but one episode.

Adam Brody as Seth, offering a bottle of beer.

Adam Brody is Toby’s other college friend, Seth, whose love life has always been more successful than Toby’s.

Matthias Clamer/FX

The novel, so interior and cerebral, at first seemed like an odd choice for the streaming TV treatment. But somehow the show pulls it off, giving the viewer the same joy of picking up what an astute writer writes. The ever-regenerative liver, Toby’s medical specialty, is a recurring motif. His son’s science project also becomes a theme generator, with forays into relativity and block universe theory that signal the show’s more intellectual aspirations and give the show an opportunity to introduce fantastic visual effects, reminiscent of the very literary HBO Max. station eleven adaptation.

The romance elements, if sometimes a little on the nose – uh, the liver – work for the most part. (Even the oxygen mask analogy manages to transcend its own cliche with a clever midseason callback.) And the nifty TV adaptation performs the same balancing act that was its source material’s major triumph, recreating the deliciously slow recalibration of the allegiance novel. You just have to stick around long enough for it to happen.

]]>
Clinical trials propel new standards of care for thyroid cancer https://rhinoplastydigest.com/clinical-trials-propel-new-standards-of-care-for-thyroid-cancer/ Sat, 12 Nov 2022 11:10:02 +0000 https://rhinoplastydigest.com/clinical-trials-propel-new-standards-of-care-for-thyroid-cancer/ Alan L. Ho, MD, PhD discusses targeted therapies such as TKIs that have shown promising efficacy in multiple patient populations as well as the agents lenvatinib and pembrolizumab. According to Alan L. Ho, MD, PhD, multidisciplinary approaches remain crucial because treatment options rely on expert knowledge to cover the wide range of thyroid cancer subgroups. […]]]>

Alan L. Ho, MD, PhD discusses targeted therapies such as TKIs that have shown promising efficacy in multiple patient populations as well as the agents lenvatinib and pembrolizumab.

According to Alan L. Ho, MD, PhD, multidisciplinary approaches remain crucial because treatment options rely on expert knowledge to cover the wide range of thyroid cancer subgroups. The broader the scope of contributions, the better the chances of expanding and delivering clinical trials tailored to patients with unmet needs.

“More than a decade ago, there were few treatment options for these diseases,” Ho said. “We now have several targeted agent-driven therapy options that have been studied in trials biologically rational clinics and targeted agents. Thyroid cancer, even more than other diseases, has [been privy to] the fruits of the genomic era [and] advances in drug development, but much remains to be done to better understand tumor biology and develop better therapies for patients.

Ho, a medical oncologist and chair of the Geoffrey Beene Junior Faculty at Memorial Sloan Kettering Cancer Center in New York, New York, is moderating the session on head, neck and thyroid cancer. On Friday, November 11, he gave a lecture entitled “Therapeutics for Thyroid Cancer” at the 40th Annual Chemotherapy Foundation Symposium® (CFS®).

In an interview with Live® Ho discussed targeted therapies such as tyrosine kinase (TKI) inhibitors which have shown promising efficacy in multiple patient populations as well as the agents lenvatinib (Lenvima) and pembrolizumab (Keytruda).

What updates in the head and neck space have been shared at CFS®?

[With the meeting,] the audience had the opportunity to learn about new standards of care and new developments in all the different types of solid malignancies outside of their specialty. In the head and neck session in particular, we had some great speakers and discussions on HPV-induced head and neck squamous cell carcinoma, which is an important topic right now given that [histology] accounts for most head and neck cancer patients in the United States. We don’t tailor our therapies well enough to the HPV status of tumors, and there are exciting new areas that can [help] define how we should do it.

another conversation [highlighted the role of] immunotherapy in squamous cell carcinomas where there have been major advances and changes in the standard of care for these patients. Beyond my own specialty, it’s always instructive to learn more about disease advances.

[In head and neck cancer] we reviewed many recent advances in developmental therapeutics for different types of thyroid cancer. It was an exciting time when we [seen the] development of numerous agents targeted against specific genetic alterations in different types of thyroid cancer histology. We reviewed the updated data [and how it affects] standards of care.

Some of the interesting biological knowledge from these trials is that a few of the same regimens will have different efficacy profiles, whether [for] non-anaplastic or anaplastic thyroid cancers. [For example,] lenvatinib and pembrolizumab have been evaluated in both anaplastic and non-anaplastic populations. Very promising response data have been published in trials involving patients with anaplastic thyroid cancer. Although toxicity, morbidity and complications remain a problem that we must pay attention to.

The landscape of non-anaplastic thyroid cancers is a bit different, but there is some interesting data regarding the role of pembrolizumab [and how it] may prolong the benefit of lenvatinib in patients who have already become resistant to it. There are different potential roles or clinical uses for these combinations depending on what [type of] thyroid cancer suffered by a patient.

What did the COSMIC-311 trial (NCT03690388) show about the survival benefits of cabozantinib monotherapy in radioiodine refractory differentiated thyroid cancer? (Table 1)1

COSMIC-311 is the third phase 3 trial that has been formed for radioactive iodine refractory thyroid cancer. This trial demonstrates for the first time PFS [progression-free survival] benefit of cabozantinib (Cabometyx) compared to placebo in patients who have already received TKI treatments, i.e. 1 or 2 previous lines, and established the efficacy of cabozantinib in the context.

You recently published a pilot clinical trial looking for patients with BRAF– mutant thyroid cancers refractory to radioactive iodine (NCT02456701). What was the rationale for this trial and what key data emerged regarding the effectiveness of the combination? (Table 2)2

My colleagues and I have demonstrated that in BRAF-mutant thyroid cancers, [first-generation] BRAF inhibitors can be quite effective for a subset of patients where you can take tumors that are no longer hungry for radioactive iodine and make them hungry for that radioactive iodine, again making it an effective treatment. But like all approaches, it was fine in that it only involved a subset of patients.

The idea behind evaluating different combinations is to see if we could increase efficiency and expand [the] use [of the available agents] to more patients with BRAF– mutant thyroid cancer. CDX-3379 targets HER3 and we have preclinical data showing that when you treat BRAF– mutant thyroid cancers with BRAF inhibitors, you can achieve upregulation of HER3 signaling. If you could repeal that, you might get more potent inhibition of the very pathways we want to inhibit to restore iodine avidity.

This trial was a very small pilot trial, 6 patients with BRAF-mutants [disease]and we were able to demonstrate that the combination [of vemurafenib and CDX-3379] was safe and that we had good efficacy in terms of restoring redifferentiation. What is needed in this area are larger studies and randomized trials to demonstrate the effectiveness of redifferentiation in refractory patients, as well as randomized comparisons to know that these combinations are better than single agents.

What is the importance of multidisciplinary management in this disease? Who else but medical oncologists can be involved in the treatment of patients?

Multidisciplinary care is essential for patients with advanced thyroid cancers. First and foremost, it is the surgeons who are, of course, important for the initial control of locally advanced disease. Even for patients with tumors in dangerous locations, surgical procedures can sometimes be considered.

The endocrinologist also helps manage TSH [thyroid stimulating hormone] deletion [and] nuclear medicine physicians [handle] radioactive iodine treatments. Radiation oncologists often [consider] palliative radiotherapy or more definitive radiotherapy for these patients. Next, medical oncologists are [handling] systemic therapeutic options, traditionally relegated to [either] radioactive iodine refractory disease, anaplastic disease, mastoid disease or recurrent metastatic disease.

There are now new paradigms where clinical trials are being evaluated with the neoadjuvant use of drugs to see if we can improve surgical outcomes for patients. With the development of better drugs [and] better approaches, it has become more and more [necessary for] multidisciplinary patient care.

What challenges remain to be met in order to develop treatments for thyroid cancer?

Metastatic differentiated thyroid cancer, refractory to radioactive iodine; anaplastic thyroid cancer; these remain incurable diseases with limited FDA-approved options. There is a need and a push to develop better, safer and more effective treatments for these patients and there is an ongoing push to better understand the biology, develop therapies and conduct clinical trials.

More and more, [thyroid cancers have] have gone from rare diseases to diseases that we can assess well in clinical trials. In settings where randomized trials may be needed, we can now do those randomized trials in settings where we need to conduct larger phase 2 trials to re-explore drug signals. We need to pursue more definitive trials to understand the effectiveness of the drugs we are developing.

References

  1. Brose MS, Robinson BG, Sherman SI, et al. Cabozantinib for previously treated radioactive iodine refractory differentiated thyroid cancer: updated results from the COSMIC-311 phase 3 trial. Cancer. Published online October 19, 2022. doi:10.1002/cncr.34493
  2. Chekmedyian V, Dunn L, Sherman E, et al. Enhancement of radioiodine uptake in BRAF-Mutant, radioiodine-refractory thyroid cancers with vemurafenib and the anti-ErbB3 monoclonal antibody CDX-3379: results of a pilot clinical trial. Thyroid. 2022;32(3):273-282. doi:10.1089/thy.2021.0565

]]>
Encore AMC Partners advises Valley Oaks Medical Sale on its sale to ApolloMed https://rhinoplastydigest.com/encore-amc-partners-advises-valley-oaks-medical-sale-on-its-sale-to-apollomed/ Wed, 09 Nov 2022 22:55:00 +0000 https://rhinoplastydigest.com/encore-amc-partners-advises-valley-oaks-medical-sale-on-its-sale-to-apollomed/ advisory. Mergers and Acquisitions. consultant. Encore AMC is pleased to announce that it served as exclusive advisor to Valley Oaks Medical Group in connection with a sale transaction with Apollo Medical Holdings. We believe that the diverse populations served by VOMG will greatly benefit from the advanced services provided by ApolloMed. » — VOMG Founder […]]]>

advisory. Mergers and Acquisitions. consultant.

Encore AMC is pleased to announce that it served as exclusive advisor to Valley Oaks Medical Group in connection with a sale transaction with Apollo Medical Holdings.

We believe that the diverse populations served by VOMG will greatly benefit from the advanced services provided by ApolloMed. »

— VOMG Founder and CEO, Guru Charan

LAS VEGAS, NEVADA, CLARK COUNTY, November 9, 2022 /EINPresswire.com/ — AMC Encore Partners (“EAMC”) is pleased to announce that it has been the exclusive advisor to Valley Oaks Medical Group (“VOMG”), which operates 15 medical clinics, nine focused on primary care and six dedicated to infusion-based specialty care, in a sale transaction to acquire 100% of the capitalization and assets entirely related to VOMG’s nine primary care clinics in Las Vegas, Houston and Fort Worth by Apollo Medical Holdings, Inc. (“AplloMed”), NASDAQ: AMEH, a leading physician-centric healthcare company focused on technology.

Based in Las Vegas, Nevada, VOMG provides value-based primary care services to its local communities, serving more than 20,000 patients, including approximately 6,000 Medicare members. Through this transaction, ApolloMed will deploy its value-based care management and operational platform to enable providers employed by VOMG to deliver the best clinical outcomes while improving the healthcare experience of its patients. The acquisition also marks ApolloMed’s entry into operating primary care clinics in Nevada and Texas, and expands ApolloMed’s membership to all nine VOMG centers.

Brandon Sim, co-CEO of ApolloMed, said, “We are delighted to welcome Valley Oaks Medical Group to the ApolloMed family, and we look forward to continuing to develop and improve value-based healthcare experiences. for new and existing patients in Las Vegas, Houston. and Fort Worth. Our partnership will allow us to bring our unique model of care to key new geographic markets, and we look forward to continuing to provide equitable, high-quality health care to underserved populations with high rates of chronic disease in these communities. .

Guru Charan, CEO of Valley Oaks Medical Group, added, “We believe the diverse populations served by VOMG will greatly benefit from the industry-leading services provided by ApolloMed, made possible by its scale, care delivery infrastructure and management systems. care. A leader in value-based care, ApolloMed is well equipped to help us continue our tradition of superior patient care. We are excited for the months and years to come as we join the ApolloMed family.

VOMG has selected EAMC to serve as exclusive advisor in the transaction. “I am delighted that we had the Encore AMC team as our advisor because of their experience in mergers and acquisitions and coaching, which made it possible to effectively manage every aspect of this transaction,” commented the founder and CEO of VOMG.

Othon Herrera, CEO of EAMC, added, “We are proud to work with Guru Charan in this primary care practice transaction. Guru and his team have built a successful primary care practice and I expect them and ApolloMed to do great things in this new partnership.

About Valley Oaks Medical Group

Valley Oaks Medical Group operates 15 medical clinics, nine primary care clinics and six specialist infusion clinics for rheumatology, neurology, infectious disease and wound care. The group provides its services to those seeking preventative health or a range of specialty services through a team of highly trained Medicare physicians to ensure the highest standard of care, while the specialty group simplifies the care process from health for his patients. For more information, visit www.valleyoaksmed.com.

About Apollo Medical Holdings, Inc.

Based in Alhambra, Calif., ApolloMed is a leading physician-centric, technology-driven, and risk-carrying healthcare management company. Leveraging its proprietary end-to-end technology solutions, ApolloMed operates an integrated healthcare delivery platform that enables providers to successfully participate in value-based care agreements, enabling them to deliver care of high quality to patients in a cost effective manner. For more information, visit www.apollomed.net.

About AMC Encore Partners

Encore AMC specializes in advisory and M&A advisory services for a wide range of industries in the small to mid-sized market, serving clients across the United States. Offering a range of advisory services, EAMC helps clients achieve their sales, acquisition, capitalization, strategic growth and interim management objectives. Additional information on the EAMC is available at www.encoreamc.partners.

Makenzie Hammond
Encore AMC Partners LLC
+1 916-848-3262
mhammond@encoreamc.partners
Visit us on social media:
LinkedIn

]]>
Canadian neurological disease and mental health experts ready to connect with Korean companies https://rhinoplastydigest.com/canadian-neurological-disease-and-mental-health-experts-ready-to-connect-with-korean-companies/ Fri, 04 Nov 2022 02:29:28 +0000 https://rhinoplastydigest.com/canadian-neurological-disease-and-mental-health-experts-ready-to-connect-with-korean-companies/ Although biopharmaceutical companies devote considerable resources each year to treating neurological diseases, many of them still do not have a cure. This is precisely the gap that Canadian biotech Ananda seeks to fill by accelerating the development of therapies for neurological diseases. Along the same lines, mental health is another often overlooked issue […]]]>

Although biopharmaceutical companies devote considerable resources each year to treating neurological diseases, many of them still do not have a cure. This is precisely the gap that Canadian biotech Ananda seeks to fill by accelerating the development of therapies for neurological diseases. Along the same lines, mental health is another often overlooked issue that struggles to objectively diagnose patients. However, Canadian company diaMentis has high hopes of changing that story with its FDA Breakthrough technology.


Ananda Business Development Associate Victoria Kwok (right) and diaMentis Vice President Jean-Denis Dubois talked about their company’s digital technology solutions in neurological disease and health mental health, respectively, at the Canadian Embassy in Seoul on Thursday.


In this context, Korea Biomedical Review sat down with Victoria Kwok, business development associate of Ananda, and Jean-Denis Dubois, vice president of diaMentis, to learn more about their digital health solutions and how they plan to find the right partners in Korea.


Platform requests


According to Kwok, Ananda is developing nervous systems on a chip for neurological research and testing by cultivating neurons in a highly organized way as opposed to traditional cultures which she described as “disorganized spaghetti” with many overlaps, making very difficult to find meaningful information. .


By providing and developing specific physiologically relevant disease models, we are able to analyze, de-risk and validate pharmaceuticals and neurodegenerative disease markers, she added.


“Our work contributes to the development of pharmaceutical drugs. As neurotoxicity is the number one cause of failure of drugs under development, we are also developing neurological models for drugs that do not treat neurological diseases,” she said. Explain.


When asked how her company differentiated itself from competitors, she replied that “organs on a chip” was an emerging market, but the company was committed to making its technology easily adoptable. The company has added a microfluidic system below the commonly used 384-well plate, which is compatible with both standard microscope readers and pre-existing lab equipment, Kwok said.


On the same note, diaMentis VP explained that they are a pioneer in the field of mental illnesses.


diaMentis Vice President Jean-Denis Dubois explains his company's digital health technology solutions in the area of ​​mental health at the Canadian Embassy in Seoul on Thursday.
diaMentis Vice President Jean-Denis Dubois explains his company’s digital health technology solutions in the area of ​​mental health at the Canadian Embassy in Seoul on Thursday.


Symptoms of mental illness all look the same in the early stages, so it’s very difficult for doctors to diagnose mental illnesses early, Dubois said.


As the retina is the window of brain function, diaMentis has developed an objective diagnostic tool that stimulates the retina with light, records the electrical response signal from the retina with electroretinography (ERG) and analysis for biomarkers that can distinguish between different mental disorders. diseases like schizophrenia, depression and bipolar disease at any stage of the disease, he explained.


The data analyzed can also predict whether a child of schizophrenic parents will be at risk of contracting this disease in five or ten years, he added.


“As we are the first to market with this disruptive technology, there is no other competition in the world for us right now,” he said confidently.


Psychiatry is the only medical specialty that still uses subjective questionnaires as diagnostic tools between doctor and patient, but diaMentis wants to provide the first objective diagnostic tool for mental illnesses, he added.


Why partner with Korea?


Regarding the reason for its partnership with Korean companies, Kwok said that Korea is at the forefront of innovation, especially in the health and research sector, which is very exciting for technology. emerging from his company, because their products require a certain level of expertise and scientific knowledge.


Ananda Business Development Associate Victoria Kwok speaks about her company's digital health technology solutions in the area of ​​mental health at the Canadian Embassy in Seoul on Thursday.
Ananda Business Development Associate Victoria Kwok speaks about her company’s digital health technology solutions in the area of ​​mental health at the Canadian Embassy in Seoul on Thursday.


“In addition, we are also interested in using our expertise in microfluidic engineering to engage with customers who have expertise in cell culture to develop custom solutions,” she continued.


In this regard, ideal partners would be pharmaceutical companies, different biotechnology companies and hospital researchers who work on models of rare diseases, she said.


The company has already partnered with a Korean company that produces cardiomyocytes to develop a related in vitro diagnostic tool.


Meanwhile, the VP of diaMentis explained that his company is looking for partners globally, but since Korea has a high burden of mental illnesses and a high number of suicides, his company is eager to find partners. in Korea. He said, “As we are still in clinical trials in Canada and the United States, we are specifically looking for partners who can help us commercialize this technology and analyze regulatory policy in South Korea.


Priority projects and future plans


Elaborating on Ananda’s priority projects, Kwok said the company’s newest product of a modeled neuromuscular junction is in its launch phase.


“This is one of the very first functional neuromuscular junction chips on the market and we are actively working with the FDA to gain approval as we applied for a multi-million dollar grant from the FDA to develop a neuromuscular junction,” she said. “We expect this to play an important role in developing treatments for neurodegenerative and neuromuscular diseases without having to collect preliminary data from patients who are already suffering.”


Currently, diaMentis is focused on successfully completing clinical trials, refining its technology, and developing a more specific electroretinography device for the company’s needs.


He added: “Due to our breakthrough designation, we also have fast-track approval and four-year sales exclusivity in the United States, so we are maintaining close contact with FDA regulators to make sure everything runs smoothly. smooth.”


Sharing some of their future plans, Kwok remarked, “Right now, we want to validate many different results on our devices, bring them to market, and expand our product platform to biopharmaceutical companies that address rare diseases.


“Ultimately, we want to enable our devices for in vitro diagnostics directly in hospitals where you could take a blood sample from a patient and quickly stratify the patient to determine whether a drug might be effective or not. “


Dubois chimed in, saying diaMentis’ short-term goal is to complete the clinical trial and then begin commercialization for the treatment of schizophrenia, bipolar and depression globally. In the long term, he expressed his wish to expand the platform for early diagnosis of other diseases such as anxiety, Alzheimer’s, Parkinson’s and autism to start treatment more quickly.

]]>
Frye Regional Medical opens its doors today in Caldwell County https://rhinoplastydigest.com/frye-regional-medical-opens-its-doors-today-in-caldwell-county/ Tue, 01 Nov 2022 15:17:11 +0000 https://rhinoplastydigest.com/frye-regional-medical-opens-its-doors-today-in-caldwell-county/ The Frye Regional Medical Center announced the opening of a new establishment in Caldwell County. The Frye Regional Healthpark was to open its doors today (November 1) at 1041 Morganton Boulevard SW in Lenoir. It is a multi-specialty outpatient establishment of 25,000 square feet which offers cardiology and family medicine practices. An inauguration celebration of […]]]>

The Frye Regional Medical Center announced the opening of a new establishment in Caldwell County. The Frye Regional Healthpark was to open its doors today (November 1) at 1041 Morganton Boulevard SW in Lenoir. It is a multi-specialty outpatient establishment of 25,000 square feet which offers cardiology and family medicine practices.

An inauguration celebration of the Caldwell Chamber of Commerce will take place on Wednesday December 7 at 3 p.m. at the new Healthpark. Visits will be offered immediately after the ceremony until 4 p.m.

The staff of the Frye Régional Healthpark includes Dr. Amada du Sablon, family doctor certified by the board of directors of Frycare Family Medicine, and Jesse Gullett, DNP, FNP, nurse family practitioner. To make an appointment with a supplier, call 828-323-2460.

FryCare Cardiology – Lenoir (formerly Piedmont Cardiology Associates), which has served Lenoir patients for over 20 years, has also been moving to the Frye Régional Healthpark. The following certified cardiologists will see new and existing patients in the new Lenoir establishment and their offices in Hickory, Connelly Springs and Lincolnton: Ghassan Alkoutami, MD; Srinivas Mikkilineni, MD; John Morrison, MD; Philippe Paspa, MD; Vincent Patrone, MD; And Pairoj Rerkpattanapipat, MD to make an appointment with a cardiologist at the Frye Régional Healthpark, call 828-754-1919.

In addition, FryCare Pain Management will open its doors in the Frye Regional Healthpark on November 7. In 2023, the providers of the Physicians Network Frycare, including neurologists, neurosurgeons, orthopedic surgeons, pulmonologists, vascular surgeons and women’s health specialists, will schedule meetings at the new location in Lenoir. Plans are also being developed for an ambulatory imaging center.

To learn more, visit FryemedCTR.com/frye-regional-healthpark.

]]>
Check positions, eligibility and how to apply https://rhinoplastydigest.com/check-positions-eligibility-and-how-to-apply/ Sat, 29 Oct 2022 15:06:47 +0000 https://rhinoplastydigest.com/check-positions-eligibility-and-how-to-apply/ AIIMS Recruitment 2022: Check Positions, Eligibility and How to Apply AIIMS Recruitment 2022: All India Institute of Medical Sciences, Bhubaneswar (AIIMS) is looking for qualified candidates to Professorships, additional professorships, associate professorships and assistant professorships. The total number of vacancies for these positions is 25. Interested candidates should review the job description and apply using […]]]>

AIIMS Recruitment 2022: Check Positions, Eligibility and How to Apply

AIIMS Recruitment 2022: All India Institute of Medical Sciences, Bhubaneswar (AIIMS) is looking for qualified candidates to Professorships, additional professorships, associate professorships and assistant professorships. The total number of vacancies for these positions is 25. Interested candidates should review the job description and apply using the link provided in the official notification. Applicant with a postgraduate degree, e.g. MD/MS, or recognized equivalent degree in the respective discipline/subject will be given preference. The deadline for receipt of applications is 15 days from the deadline.

Applicants are advised to apply for the position before the deadline. No applications will be accepted after the stipulated time/date. Incomplete entries and entries received after the specified time/date will be REJECTED. Full details regarding this position are given in this article such as AIIMS Recruitment Official notification 2022, age limit, eligibility criteria, salary and much more.

Qualification for AIIMS Recruitment 2022

Teacher

1. A postgraduate degree, e.g. MD/MS or recognized equivalent degree in the respective discipline/subject.

2. M.Ch. for surgical subspecialties and DM for medical subspecialties (recognized 2-year or 3-year or 5-year courses) or an equivalent recognized qualification.

To note: For more details, interested candidates are advised to go to the official invitation.

Experience for AIIMS 2022 Recruitment

Teacher

1. Fourteen years of teaching and/or research experience in a recognized institution in the field of the specialty after obtaining the qualification diploma of MD/MS or an equivalent recognized qualification.

2. Twelve years of teaching and/or research experience in a recognized institute in the field of specialty after obtaining the degree of M.Ch./DM (2 years or 5 years course recognized after MBBS) in the respective discipline/subject or a title recognized as equivalent to it.

Additional teacher: Ten years of teaching and/or research experience in a recognized institution in the field of the specialty after obtaining the degree of MD/MS or an equivalent recognized qualification.

To note: For more details, interested candidates are invited to go to the official invitation.

Salary Details for AIIMS Recruitment 2022

Age Limit for AIIMS 2022 Recruitment

1. Professor/Additional Professor: – Not exceeding 58 (Fifty-Eight) years of age on the deadline.

2. Associate Professor / Assistant Professor: – Not exceeding 50 (fifty) years of age at the deadline.

3. No age relaxation would be available for SC/ST/OBC/EWS candidates applying for non-reserved vacancies.

Application Fee for AIIMS Recruitment 2022

1. For Non-booked/OBC/EWS applicants, Rs.1000. Applicants can pay the prescribed application fee online by clicking on the link provided on the website while completing the online application.

2. Application fees once paid will not be refunded under any circumstances.

3. No application fee for SC/ST/PwBD/Women candidates from any community.

How to Apply to AIIMS Recruitment 2022

Applicants after applying through the online mode must submit the hard copy of the duly signed online application form and self attested copies of matriculation certificate, MBBS degree certificate/mark sheets, MD/MS/DM / MCh or equivalent certificates / grade sheets, Certificates of teaching / research experiences, etc. in support of meeting the essential criteria of age, educational qualification, teaching/research experiences, etc., and others in support of their application to this institute. Applicants should ensure that their hard copy of the application and other relevant documents mentioned above should reach the Institute within 15 days of the deadline. The certificate of experience must clearly indicate the duration of the experience (“from” to “until”), the nature of the experience (either teaching or research), etc. Applicants may only mention teaching experiences recognized by the MCI/Gov. . from India.

Signed hard copies of the online application along with all certificates/documents mentioned above should be sent via Speed ​​Post/Courier etc. within the time limit. The mailing address for the hard copy of the application and relevant documents is as follows:

To read the official notification, click here

Disclaimer: The recruitment information provided above is for informational purposes only. The recruitment information above is taken from the official website of the Organization. We do not provide any recruitment guarantees. Recruitment should be conducted in accordance with the official recruitment process of the company or organization that advertised the recruitment position. We do not charge any fees for providing this employment information. Neither the author nor Studycafe and its affiliates accept any responsibility for any loss or damage of any kind arising from any information contained in this article or for any actions taken in reliance thereon.

]]>
Phase II Data Shows Litifilimab’s Treatment Potential for CLE | Latest news for doctors, nurses and pharmacists https://rhinoplastydigest.com/phase-ii-data-shows-litifilimabs-treatment-potential-for-cle-latest-news-for-doctors-nurses-and-pharmacists/ Thu, 27 Oct 2022 02:00:54 +0000 https://rhinoplastydigest.com/phase-ii-data-shows-litifilimabs-treatment-potential-for-cle-latest-news-for-doctors-nurses-and-pharmacists/ In part B* of the in two parts 16-week LILAC study, anti-BDCA2** antibody litifilimab reduced skin disease activity in people with cutaneous lupus erythematosus (CLE). “CLE causes irreversible damage and disfigurement, impairs patients’ quality of life, and is associated with depression, anxiety, and fatigue,” the researchers said. Topical glucocorticoids and antimalarial drugs are considered first-line […]]]>

In part B* of the in two parts 16-week LILAC study, anti-BDCA2**
antibody litifilimab reduced skin disease activity in people with cutaneous lupus erythematosus (CLE).

CLE causes irreversible damage and disfigurement, impairs patients’ quality of life, and is associated with depression, anxiety, and fatigue,” the researchers said. Topical glucocorticoids and antimalarial drugs are considered first-line treatment options for CLE. However, there is insufficient evidence supporting the benefit of glucocorticoids; with antimalarials, responses were inconsistent. [J Eur Acad Dermatol Venereol 2017;31:389-404;
Br J Dermatol 2017;177:188-196; Cochrane Database Syst Rev 2021;3:CD007478]

“This phase II trial involving participants with active, histologically confirmed CLE with or without manifestations [of
systemic lupus erythematosus (SLE)] showed a significant dose-response relationship for the primary endpoint of the CLASI-A*** score, a measure of skin disease activity, over a 16-week period,” the researchers said.

Part B of LILAC included 132 participants with moderate to severe subacute#
or chronic## KEY (or both). They were randomized to receive litifilimab SC 50, 150, or 450 mg (n=26, 25, and 48, respectively) or placebo (n=33) at weeks 0, 2, 4, 8, and 12.
Eligible participants had also received prior treatment with topical or antimalarial agents (or both) that failed or made side effects intolerable. [N Engl J Med
2022;387:321-331]

Mean baseline CLASI-A scores were 15.2, 18.4, 16.5, and 16.5 for the litifilimab 50, 150, and 450 mg and placebo arms, respectively.

At week 16, baseline CLASI-A scores fell in all arms, more so with litifilimab (least squares mean [LSM] changes,
-38.8, -47.9, and -42.5% with 50, 150, and 450 mg doses, respectively) than with the placebo (change in LSM,
–14.5%). “[The] negative values ​​indicate improvement from baseline,” the researchers noted.
Using the best-fit dose-response model, these were found to be significant.

Between litifilimab and placebo, the LSM differences in CLASI-A score changes from baseline to week 16 were -24.3, -33.4, and -28.0 percentage points for the respective 50 doses. , 150 and 450 mg. However, the summary dose-response analysis did not compare the three doses to each other.

Three cases of hypersensitivity have been reported with litifilimab, leading to discontinuation of treatment. Viral infections have also been reported with the use of litifilimab [though unspecified]; flu, oral herpes, shingles, upper respiratory tract infection, rash).

Seven litifilimab recipients experienced serious adverse events, two had SLE flares (with litifilimab 150 mg) and one had a severe case of herpes zoster meningitis (with litifilimab 50 mg) approximately 4 months after receiving the last dose .

“The high rate of shingles among the participants underscores the importance of giving patients the shingles vaccine before starting these medications,”
said
Doctor Daniel Wallace of Cedars-Sinai Medical Center, Los Angeles, California, USA, in an accompanying editorial.
[N Engl J Med 2022;387:939-940]

Alteration of upstream lupus inflammatory pathways

“[The findings] and the subsequent FDA approval of anifrolumab, a monoclonal antibody that binds to and internalizes the type I interferon receptor, for the treatment of SLE, suggest the possibilities of altering pathways upstream of the system innate immune system, Wallace noted.

CLASI-A score improvements with litifilimab reported in LILAC
surpassed those seen in previous reports. However, direct comparisons between the studies cannot be made because they had different patient populations, Wallace pointed out.

“The results are nonetheless all provocative for phase II trials…Lupus has lagged behind its rheumatic disease cousins, such as vasculitis and rheumatoid arthritis, in drug development,” said noted Wallace. “The findings…encourage further exploration of interventions that affect lupus inflammatory pathways upstream in the lupus innate immune system.”

Larger and longer trials are warranted to validate the efficacy and safety of litifilimab for the treatment of a lifelong disorder.

]]>
Los Angeles doctor elected president of CMA Chamber https://rhinoplastydigest.com/los-angeles-doctor-elected-president-of-cma-chamber/ Sun, 23 Oct 2022 20:25:16 +0000 https://rhinoplastydigest.com/los-angeles-doctor-elected-president-of-cma-chamber/ October 23, 2022 Los Angeles family medicine physician Jack Chou, MD, was elected the new president of the California Medical Association (CMA) House of Delegates today at the association’s annual meeting. He previously served as Vice President for three years. Joining Dr. Chou on the dais will be San Francisco’s new vice president-elect dermatologist Lawrence […]]]>







October 23, 2022

Los Angeles family medicine physician Jack Chou, MD, was elected the new president of the California Medical Association (CMA) House of Delegates today at the association’s annual meeting. He previously served as Vice President for three years. Joining Dr. Chou on the dais will be San Francisco’s new vice president-elect dermatologist Lawrence Cheung, MD

Dr. Chou has divided his clinical time between primary care, emergency care, and hospital duties at Kaiser Baldwin Park Medical Center since 1999. He is the physician in charge of the Department of Family Medicine at Kaiser Baldwin Park Medical Center, Family Medicine Medical Office Building since 2006. Dr. Chou became Service Chief of the Department of Family Medicine in July 2018, overseeing five medical offices.

Dr. Chou is a Partner of the Southern California Permanente Medical Group (SCPMG) and is the Regional Chair of Health Information Management and Regional Co-Chair of the Southern California Permanente Medical Group Digitization Oversight Committee.

Since medical school, Dr. Chou has embraced leadership at all levels – local, state and national. Dr. Chou has been a member of the CMA and the Los Angeles County Medical Association (LACMA) since 1992 and has been a member of the American Medical Association since 1996.

Dr. Chou has been a member of the CMA House of Delegates since 2001. He was elected to represent LACMA on the CMA Board of Directors in 2010 and served on the CMA Ethics Affairs Council from 2011 to 2016. Dr. Chou is also active in his local, state, and national specialty societies, including serving as president and speaker of the California Academy of Family Physicians Congress of Delegates.

Dr. Chou grew up in a small rural town in Taiwan and later earned his Bachelor of Science in Biology from the University of Miami, Florida, and his medical degree from the University of Southern California, Los Angeles. He completed his family medicine residency at Kaiser Permanente Woodland Hills Family Medicine Residency in Woodland Hills, CA.

Dr. Chou and his wife, Kathy, are the proud parents of twin daughters, Sarah and Samantha, and one son, Nathan. He spends most of his free time traveling with his family as part of the education of his children.

The full 2022-2023 CMA Executive Committee includes:

  • Chair: Donaldo Hernandez, MD, Santa Cruz

  • President-Elect: Tanya W. Spirtos, MD, Redwood City

  • Board Chair: Shannon L. Udovic-Constant, MD, San Francisco

  • Vice Chairman of the Board: Sergio R. Flores, MD, San Diego

  • Speaker of the Chamber: Jack Chou, MD, Los Angeles

  • House Vice President: Lawrence Cheung, MD, San Francisco

Come back

]]>